You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Augmented Reality Surgical Visualization Tool for Combat Casualty Care

    SBC: AUGMNTR, INC.            Topic: DHA191001

    New technologies like digital simulators (avatar) and augmented reality (AR) show promise in enhancing training for combat medics and advancing the treatment of time critical, traumatic injuries. Initial development efforts have focused on marrying synthetic content with a real-world view within the augmented reality environment. Great strides have been made to make this new viewing environment ub ...

    SBIR Phase II 2023 Department of DefenseDefense Health Agency
  2. Dry Electrode Flight helmet Integrated Eeg System (DEFIES), Phase II

    SBC: QUANTUM APPLIED SCIENCE & RESEARCH INC            Topic: DHA222001

    The National Commission on Military Aviation Safety determined that between 2013 and 2020, 224 lives, and 186 aircraft were lost due to military aviation mishaps amounting to losses of $11.6 billion. It is well documented that there is a negative impact on mission performance and an increased risk of accidents associated with sleep deprivation, extended time on intense attention demanding tasks, p ...

    SBIR Phase II 2023 Department of DefenseDefense Health Agency
  3. Determining the Need and Compatibility of a Metalloprotease Inhibiter with Broad Spectrum Envenomation Treatment

    SBC: OPHIREX, INC.            Topic: DHA18002

    SEQUENTIAL SBIR PHASE II TECHNICAL OBJECTIVES AND APPROACH All activities of this proposed Sequential SBIR II are directed toward determining the incremental benefit of adding a metalloprotease inhibitor to varespladib for improving recovery and return to duty time following snakebite envenoming. The work will also advance the TRL of the metalloprotease inhibitor in order to support a SBIR III eff ...

    SBIR Phase II 2023 Department of DefenseDefense Health Agency
  4. Portable Phage Preparation Technology for Field Application

    SBC: CFD RESEARCH CORPORATION            Topic: A20BT023

    Bacteriophages (phages) are becoming important therapeutic candidates against multidrug resistant (MDR) bacterial infections. There is a need to isolate and concentrate phages collected from the field to enhance specimen storage stability for long-distance transport to specialized laboratories for subsequent analysis. Environmental phage preparation requires expensive, bulky instrumentation and in ...

    STTR Phase II 2023 Department of DefenseDefense Health Agency
  5. Direct Blood Volume Analyzer for Improvement of Combat Casualty Care

    SBC: DAXOR CORPORATION            Topic: A18122

    Hemorrhage is the leading cause of preventable combat mortality. Despite recent advances in care, sustaining adequate tissue perfusion remains a challenge. Current practice for determining fluid status to guide battlefield resuscitation and transfusion, including clinical assessment and surrogate markers, often lag symptomatic diagnosis or misdiagnose the severity of volume derangement. Care is fu ...

    SBIR Phase II 2023 Department of DefenseDefense Health Agency
  6. Chemical-Imaging Registration and Multi-modal Analysis

    SBC: INTELLISENSE SYSTEMS INC            Topic: CBD212001

    To address the Chemical and Biological Defense (CBD) agency’s need for a new deep learning (DL)-based threat detection solution that fuses imaging sensors and chemical/biological sensors to detect and locate concealed chemical threats, Intellisense Systems, Inc. (Intellisense) proposes to complete the development of the new Chemical-Imaging Registration and Multi-modal Analysis (CIGMA) solution. ...

    SBIR Phase II 2023 Department of DefenseOffice for Chemical and Biological Defense
  7. Enhanced Combat Tourniquet with Modular Wound Infection Prevention Capabilities

    SBC: TDA RESEARCH, INC.            Topic: DHA221001

    Tourniquets are an important medical tool that are used to apply pressure to a wounded limb or extremity to restrict and prevent blood loss. Tourniquets can be used during some surgical procedures and in emergencies to stop severe traumatic bleeding. As the U.S. Military faces peer and near-peer adversaries, the time-to-evacuation for wounded warfighters is expected to increase. Likewise, the diff ...

    SBIR Phase II 2023 Department of DefenseDefense Health Agency
  8. Passive Standoff Millimeter Wave Imaging System

    SBC: SYGHT INC            Topic: CBD213002

    Syght will develop a stand-off passive millimeter wave imaging system for detection of weapons or Person-Borne Improvised Explosive Devices (IEDs) concealed under clothing or in bags and for detection of Leave-Behind IEDs through obscurants such as camouflage, dust, and smoke.

    SBIR Phase II 2023 Department of DefenseOffice for Chemical and Biological Defense
  9. SEAL: A generalized framework for deploying a secure application lifecycle management process with CI/CD

    SBC: EP ANALYTICS, INC..            Topic: DTRA212004

    The Defense Threat Reduction Agency (DTRA) uses High-Fidelity (HF) computer codes, many of which are legacy codes that have evolved over many years, to investigate weapon effects phenomenology and techniques for countering Weapons of Mass Destruction (WMD). As DTRA’s reliance on HF codes for tasks critical to national security continues to increase, transitioning such codes from legacy coding pr ...

    SBIR Phase II 2023 Department of DefenseDefense Threat Reduction Agency
  10. N3: Negative, Nerve-Targeted Nanocarriers

    SBC: NOU SYSTEMS INC            Topic: DHA213007

    To defeat OP nerve agents, we must match both their potency and access to the synaptic cleft. Unfortunately, the most potent organophosphate antidotes cannot access neurons from the systemic circulation. Phosphotriesterase (PTE) enzyme mutants are too large, and small, cationic oximes are too charged to cross the blood-brain-barrier or blood-nerve-barrier in appreciable quantities. State-of-the-ar ...

    SBIR Phase II 2023 Department of DefenseDefense Health Agency
US Flag An Official Website of the United States Government